<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="332">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156827</url>
  </required_header>
  <id_info>
    <org_study_id>TB006AIS2103</org_study_id>
    <nct_id>NCT05156827</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke</brief_title>
  <official_title>A Phase 2 Double-blind, Randomized, Multi-center, Parallel-group Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Patients With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TrueBinding, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TrueBinding, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to determine the clinical efficacy of TB006 in participants with&#xD;
      acute ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2022</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Neurological Function on the National Institutes of Health Stroke Scale (NIHSS) through Day 104</measure>
    <time_frame>Baseline through Day 104</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Improvement on the NIHSS at Day 36 and Sustained through Day 104</measure>
    <time_frame>Day 36 through Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Neurological Function on the NIHSS at Day 36</measure>
    <time_frame>Baseline; up to Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Improvement on the Modified Rankin Scale (mRS) at Day 36 and Sustained through Day 104</measure>
    <time_frame>Day 36 through Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Fugl-Meyer Assessment (FMA) Total Score at Day 36 and Day 104</measure>
    <time_frame>Baseline; Day 36 and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Montreal Cognitive Assessment (MoCA) Total Score at Day 36 and Day 104</measure>
    <time_frame>Baseline; Day 36 and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>up to Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Clinical Laboratory Parameter Values</measure>
    <time_frame>up to Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Vital Sign Values</measure>
    <time_frame>up to Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant 12-Lead Electrocardiogram Findings</measure>
    <time_frame>up to Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) Score at Day 104</measure>
    <time_frame>Baseline; Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Physical Examination Findings</measure>
    <time_frame>up to Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Neurological Examination Findings</measure>
    <time_frame>up to Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-drug Antibodies at Day 1, Day 36, and Day 104</measure>
    <time_frame>Day 1, Day 36, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Area Under the Concentration Time Curve over a Dosing Interval (AUC0-tau) at Steady State</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Concentration at the End of a Dosing Interval (Ctrough)</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Terminal Elimination Phase Half-life (t1/2)</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Cmax (tmax)</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clearance (CLss) at Steady State</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Volume at Steady State (Vss)</measure>
    <time_frame>Day 1 (Predose), Day 29 (Predose), Day 36, Day 64, and Day 104</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>TB006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an intravenous (IV) infusion of TB006 1000 milligrams (mg) once weekly for 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive an IV infusion of normal saline once weekly for 5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB006</intervention_name>
    <description>TB006 diluted in normal saline, administered through IV infusion over an hour</description>
    <arm_group_label>TB006</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline administered through IV infusion over an hour</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18 and 40 kilograms per meters squared (kg/m^2),&#xD;
             inclusive&#xD;
&#xD;
          -  Clinical diagnosis of acute ischemic stroke (AIS) in anterior circulation, supported&#xD;
             by acute brain computed tomography (CT) scan or magnetic resonance imaging (MRI)&#xD;
             consistent with the clinical diagnosis.&#xD;
&#xD;
          -  Able to be randomized and dosed within 7 days of index stroke event. The last known&#xD;
             awake time will be used for participants whose stoke occurred during sleep.&#xD;
&#xD;
          -  National Institute of Health Stroke Scale total score of 7 to 21, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of severe stroke on imaging (e.g., sulcal effacement or blurring of&#xD;
             gray-white junction in greater than 1/3 of middle cerebral artery [MCA] territory,&#xD;
             Alberta Stroke Program Early CT [ASPECT] score of 0 to 4 based on head CT, acute&#xD;
             infarct volume on MRI diffusion weighed imaging â‰¥70 milliliters (mL) based on acute&#xD;
             imaging studies performed under the standard of care&#xD;
&#xD;
          -  Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and&#xD;
             available acute imaging studies performed under the standard of care&#xD;
&#xD;
          -  Evidence of seizure at the onset of index stroke&#xD;
&#xD;
          -  Evidence of acute myocardial infarction (MI) at Baseline, including any of the&#xD;
             following:&#xD;
&#xD;
               1. Acute ST elevation MI;&#xD;
&#xD;
               2. Acute decompensated heart failure, or New York Heart Association Class III/IV&#xD;
                  heart failure;&#xD;
&#xD;
               3. Admission for an acute coronary syndrome, MI, cardiac arrest, or non-voluntary&#xD;
                  coronary intervention (percutaneous coronary intervention or coronary artery&#xD;
                  surgery) within the past 3 months.&#xD;
&#xD;
               4. QT interval corrected using Bazett's formula (QTcB) &gt;520 milliseconds (msec)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TrueBinding, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>TrueBinding, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TrueBinding, Inc.</last_name>
    <phone>650-847-1117</phone>
    <email>info@truebinding.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIS</keyword>
  <keyword>TB006</keyword>
  <keyword>stroke</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

